Which medication is specifically approved for adjunct use in Major Depressive Disorder (MDD)?

Brexiprazole is specifically approved as an adjunct treatment for Major Depressive Disorder (MDD). This medication is an atypical antipsychotic that can be used in combination with an antidepressant when a patient is experiencing an inadequate response to their current antidepressant therapy. Its role is to help enhance the effects of standard antidepressant medications, providing a more comprehensive treatment approach for individuals struggling with MDD.

Fluoxetine, while an effective antidepressant, is primarily used as a standalone treatment for MDD rather than as an adjunct medication. Procarbazine is used in the treatment of certain types of cancers and does not have any approved use in MDD. Linezolid is an antibiotic that treats bacterial infections, and it is not indicated for the treatment of depression. Therefore, brexiprazole stands out as the medication that is specifically aimed at supporting the main treatments for Major Depressive Disorder when added as an adjunct.